Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 16/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19079174 | 0.83 | SMYD3 (0.56) | SMYD3NPC1RAB9ATSHRPSMB8 | |
| SCHEMBL19079475 | 0.80 | SMYD3 (0.58) | SMYD3PSMB8PSMB9PSMB5 | |
| SCHEMBL19079507 | 0.80 | SMYD3 (0.58) | SMYD3PSMB8PSMB9PSMB5 | |
| SCHEMBL19734278 | 0.79 | SMYD3 (0.56) | SMYD3NPC1RAB9ATSHRPSMB8 | |
| SCHEMBL19079203 | 0.79 | NPC1 (0.59) | SMYD3NPC1RAB9ATSHRPSMB8 | |
| SCHEMBL19079205 | 0.79 | NPC1 (0.55) | SMYD3NPC1RAB9ATSHRPSMB8 | |
| SCHEMBL19079204 | 0.78 | NPC1 (0.61) | SMYD3NPC1RAB9ATSHRPSMB8 | |
| SCHEMBL19079165 | 0.77 | RAB9A (0.55) | SMYD3NPC1RAB9ATSHR | |
| SCHEMBL27006417 | 0.76 | PSMB8 (0.50) | SMYD3NPC1RAB9ATSHRPSMB8 | |
| SCHEMBL27137936 | 0.76 | PSMB8 (0.50) | SMYD3NPC1RAB9ATSHRPSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428029-B2 | Isoxazole carboxamide compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885NPC1 3888/4885RAB9A 759/4885 |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885NPC1 3888/4885RAB9A 759/4885 |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885NPC1 3842/4885RAB9A 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.